New hope for kidney cancer patients whose disease returns after standard therapy
Disease control
Recruiting now
This study tests a new drug called zanzalintinib, either alone or with the immunotherapy nivolumab, in people with advanced kidney cancer that got worse after initial treatment. About 70 adults will take part. The goal is to see if the combination shrinks tumors better than the d…
Phase: PHASE2 • Sponsor: Karie Runcie • Aim: Disease control
Last updated May 10, 2026 08:43 UTC